Pulse Biosciences (NASDAQ: PLSE) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.
This is a summary of recent ratings and recommmendations for Pulse Biosciences and Agilent Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agilent Technologies has a consensus price target of $72.52, suggesting a potential upside of 12.55%. Given Agilent Technologies’ higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Pulse Biosciences.
Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 0.9%. Pulse Biosciences does not pay a dividend. Agilent Technologies pays out 25.4% of its earnings in the form of a dividend. Agilent Technologies has raised its dividend for 2 consecutive years.
This table compares Pulse Biosciences and Agilent Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Pulse Biosciences has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
Valuation and Earnings
This table compares Pulse Biosciences and Agilent Technologies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Pulse Biosciences||N/A||N/A||-$25.56 million||N/A||N/A|
|Agilent Technologies||$4.47 billion||4.65||$684.00 million||$2.36||27.30|
Agilent Technologies has higher revenue and earnings than Pulse Biosciences.
Insider & Institutional Ownership
10.9% of Pulse Biosciences shares are held by institutional investors. 6.7% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Agilent Technologies beats Pulse Biosciences on 9 of the 13 factors compared between the two stocks.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Agilent Technologies Company Profile
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment services; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients. The Agilent CrossLab segment offers GC and LC columns, sample preparation products, custom chemistries, and various laboratory instrument supplies; and startup, operational, training, and compliance support, as well as asset management and consultation services. The company markets its products through direct sales, electronic commerce, resellers, manufacturers' representatives, and distributors. It has collaboration with the University of Southern California Michelson Center for Convergent Bioscience. Agilent Technologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.